Gland Pharma Limited Stock Price Today (NSE: GLAND)

Gland Pharma Limited

2826.6068.90 (2.38%)
Market Closed

Fundamental Score

...

Gland Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Gland Pharma Limited share price today is 2826.60, down 2.38% on NSE/BSE as of 16 September 2026. Gland Pharma Limited (GLAND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 46.63K (Cr). The 52-week high for GLAND share price is 3042.00 and the 52-week low is 1573.60. At a P/E ratio of 41.26x, GLAND is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 10.53% and a debt-to-equity ratio of 0.02.

Gland Pharma Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
3042.00
Low
2610.10
Volume
9.6L
Change
+10.95%

Gland Pharma Limited share price chart: 10.95% return over the past month. 52-week high ₹3042.00, 52-week low ₹1573.60.

Gland Pharma Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
2877.002914.202792.402826.607.49L (Cr)
2930.002940.002856.902895.504.98L (Cr)
2940.002950.102882.002922.303.89L (Cr)
3031.003031.002918.902946.903.69L (Cr)
2959.303033.902938.603026.2015.61L (Cr)
2979.902979.902901.902959.307.10L (Cr)
2929.603042.002916.902974.3010.31L (Cr)
2915.002969.002851.102932.4029.78L (Cr)
2870.002948.002847.602907.901.89L (Cr)
2915.002930.002803.002868.405.56L (Cr)

Gland Pharma Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
2885.703042.002792.402826.60-2.05%
2505.603039.802494.102885.80+15.17%
2495.002586.002360.002502.90+0.32%
2278.602528.302167.802495.00+9.50%
1750.802396.001748.002250.00+28.51%
1701.701832.001652.001750.80+2.89%
1780.001802.101573.601696.10-4.71%
1815.801984.901748.901822.20+0.35%
1716.601874.801650.001846.60+7.57%
1768.201815.001629.601722.00-2.61%
1942.702034.001730.001759.60-9.43%
1992.002026.101889.001928.90-3.17%

Returns & Performance

Poor

Return on Equity (ROE)

10.53%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

14.57%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

29.53%

Average operating profit margin over 5 years

Dividend Yield

0.81%

Annual dividend as % of current share price

Gland Pharma Limited Valuation Check

Poor

Price to Earnings (P/E)

41.26x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

51.83%

% shares held by company founders/management

Average

FII Holding

7.29%

% shares held by foreign institutional investors

Excellent

DII Holding

33.36%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

47.09%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

19.57%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

13.18%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-0.23%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

0.60%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.02x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

45.01x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

2.07K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Gland Pharma Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GLAND across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Operating Margins (29.53%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (47.09%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (19.57%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (13.18% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.02)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (45.01x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 4.33)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹2069.23 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (51.83%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Strong Institutional Confidence (FII+DII: 40.65%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Premium Valuation Risk (P/E: 41.26x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (5.09x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Weak Earnings Growth (-0.23% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (0.60% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Gland Pharma Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Gland Pharma Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
61.2/100
2827
₹46627.59
41.3
Average
10.53%
Average
14.57%
Average
0.0
Excellent
0.60%
Average
13.18%
Good
0.81%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9468
₹250888.75
85.9
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4940
₹167182.32
78.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1372
₹110828.94
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1941
₹104867.93
95.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1683
₹96839.82
26.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2101
₹96054.51
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95565.75
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2294
₹94729.81
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Gland Pharma Limited PE Ratio History

Historical price-to-earnings ratio for GLAND — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202542.40₹1722.0040.6x
FY 202446.89₹1779.3537.9x
FY 202347.43₹1924.5040.6x
FY 202273.64₹1576.5521.4x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Gland Pharma Limited Dividend History

Annual cash dividends paid by GLAND — dividend yield 0.81%

Financial YearDividends Paid (₹ Cr)
FY 2025329.49 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Gland Pharma Limited Quarterly Performance

Latest quarterly metrics for GLAND — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

19.57%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

47.09%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

13.18%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

0.60%

Compounded annual net profit growth over 5 years

Gland Pharma Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GLAND — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
2662
▲ Price above SMA 50 — Short-term bullish
SMA 200
2057
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
846K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Gland Pharma Limited Financial Statements

Annual income statement, balance sheet and cash flow for Gland Pharma Limited (GLAND) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Gland Pharma Limited

Loading latest quarterly results...

About GLAND (Gland Pharma Limited)

Gland Pharma Ltd is a global pharmaceutical powerhouse specializing in sterile injectables, a critical and complex field requiring precision and expertise. They develop, manufactur...e, and market a diverse range of injectable products, catering to various therapeutic areas and dosage forms. The company distinguishes itself through its commitment to quality and regulatory compliance, adhering to stringent international standards across its facilities. From vials and ampoules to pre-filled syringes and lyophilized products, Gland Pharma offers a comprehensive portfolio to meet the evolving needs of healthcare providers and patients worldwide. Their expansive geographical reach ensures that vital medications are accessible to communities across the globe, solidifying their position as a trusted provider of essential injectable pharmaceuticals. Beyond its manufacturing capabilities, Gland Pharma also invests significantly in research and development, with a focus on developing innovative injectable formulations and enhancing existing products. They are actively involved in the development of complex molecules, including peptides and biosimilars, signaling a forward-thinking approach to address unmet medical needs. This commitment to innovation extends to exploring novel drug delivery systems and formulations that improve patient outcomes and reduce healthcare costs. By combining its robust manufacturing infrastructure with a dynamic R&D pipeline, Gland Pharma is strategically positioned to capitalize on emerging opportunities in the global injectable market and maintain its competitive edge in the long term. This positions them as more than just a manufacturer, but an innovator in the space. Gland Pharma’s success is underpinned by a strong foundation of technical expertise, quality control systems, and a customer-centric approach. The company fosters a culture of continuous improvement, constantly seeking ways to optimize its processes and enhance the value it delivers to its partners. Their commitment to sustainability is evident in their environmentally conscious manufacturing practices and responsible sourcing of raw materials. This dedication to ethical and sustainable practices aligns with the growing demand for responsible corporate citizenship within the pharmaceutical industry. Ultimately, Gland Pharma strives to be a reliable and trusted partner, delivering high-quality injectable medications that improve the lives of patients around the world.

Company Details

Symbol:GLAND
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Srinivas Sadu
Executive Chairman
Mr. Shyamakant Giri
Chief Executive Officer
Mr. Ravi Shekhar Mitra
Chief Financial Officer

GLAND Share Price: Frequently Asked Questions

What is the current share price of Gland Pharma Limited?

Gland Pharma Limited (GLAND) trades at ₹2826.60 on NSE and BSE. Market cap ₹46.63K (Cr). Educational data only.

What is the P/E ratio of Gland Pharma Limited?

Gland Pharma Limited has a P/E of 41.26x vs industry average 34.89x.

What is the Bull Run score for Gland Pharma Limited?

Gland Pharma Limited has a Bull Run score of 61.2/100 based on 25+ financial parameters.

Does Gland Pharma Limited pay dividends?

Gland Pharma Limited has a dividend yield of 0.81%. Past dividends don't guarantee future payments.

What is the ROE of Gland Pharma Limited?

Gland Pharma Limited has ROE of 10.53%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Gland Pharma Limited?

Gland Pharma Limited has debt-to-equity of 0.02.

Is Gland Pharma Limited a good investment?

Bull Run gives Gland Pharma Limited a score of 61.2/100. This is not investment advice — consult a SEBI-registered advisor.